

№449, 27-dekabr, 2021 y.

**COVID
19**

COVID-19 ga qarshi vaksinalarning
ishlanmalari bo'yicha

DAYJEST

O'zbekiston Respublikasi Innovatsion rivojlanish vazirligi huzuridagi
Ilmiy-texnik axborot markazi











Toshkent-2021

Jahonda pandemiya bilan bog'liq vaziyat

2021 y. 26-dekabr holatiga ko'ra

Umumiy zararlanganlar soni	-	279 824 411	(+ 493 546)
Sog'ayganlar soni	-	250 026 789	(+ 355 716)
Vafot etganlar soni	-	5 413 265	(+ 4 138)

Mamlakatlar bo'yicha bemorlar soni

	AQSh	-	53 026 765	(+ 40 458)
	Hindiston	-	34 786 802	(+ 6 987)
	Braziliya	-	22 234 626	(+ 3 889)
	Buyuk Britaniya	-	11 891 292	(+ 122 186)
	Rossiya	-	10 368 299	(+ 24 946)
	Turkiya	-	9 286 986	(+ 20 470)
	Fransiya	-	9 088 371	(+ 104 611)
	Germaniya	-	6 999 476	(+ 17 248)
	Eron	-	6 182 905	(+ 1 121)
	O'zbekiston	-	198 242	(+ 143)

Manba: <https://www.worldometers.info/coronavirus/>



O'zbekistonda COVID-19 qarshi vaksinatsiya bo'yicha hisobot

2021 y. 25-dekabr holatiga ko'ra

Hududlar	Jami emlanganlar soni	Bir kunda emlanganlar soni
Qoraqalpog'iston Respublikasi	1 984 334	4 287
Andijon viloyati	3 653 155	17 920
Buxoro viloyati	2 163 660	10 233
Jizzax viloyati	1 391 218	2 377
Qashqadaryo viloyati	2 915 281	12 016
Navoiy viloyati	1 288 035	3 105
Namangan viloyati	3 662 983	9 830
Samarqand viloyati	4 527 574	31 836
Surxondaryo viloyati	3 090 187	13 612
Sirdaryo viloyati	847 806	2 026
Toshkent viloyati	3 661 767	19 804
Farg'ona viloyati	4 217 242	21 280
Xorazm viloyati	2 316 580	7 537
Toshkent sh.	2 781 134	23 938
Jami	38 500 956	179 801

Manba: SSV matbuot kotibi // <https://t.me/ssvmatbuotkotibi>



JSST tomonidan baholash jarayonida COVID-19 ga qarshi vaksinlarning holati

2021 y. 24-dekabr holatiga ko'ra


№	Ishlab chiqaruvchi	Vaksina nomi	Platforma	Arizalarni qabul qilish	Uchrashuv o'tkazish	Ma'lumotnomani ko'rib chiqish uchun qabul qilish	Baholash holati	Kutilayotgan chiqish sanasi
1	Pfizer	BNT162b2/COMIRNATY	mRNK	+	+	+	Yakunlangan	Tasdiqlangan 31.12.2020
2	AstraZeneca/University of Oxford	AZD1222	Recombinant replication defective chimpanzee adenovirus expressing surface glycoprotein SARS-CoV-2	+	+	+	Yakunlangan	Tasdiqlangan 15.02.2021
3	Janssen	Ad26.COV2.S	Recombinant vector vaccine against adenovirus type 26 (Ad26), incapable of replication, encoding Spike (S) protein (SARS-CoV-2)	+	+	+	Yakunlangan	Tasdiqlangan 12.03.2021
4	SK BIOscience - AstraZeneca/University of Oxford	AZD1222	=	+	+	+	Yakunlangan	Tasdiqlangan 16.04.2021
5	Serum institute of India	Covishield	Recombinant adenoviral vector ChAdOx1 encoding the Spike SARS-CoV-2 protein antigen	+	+	+	Yakunlangan	Tasdiqlangan 16.04.2021
6	Moderna	mRNA-1273	mRNA-based vaccine encapsulated in lipid nanoparticles	+	+	+	Yakunlangan	Tasdiqlangan 30.04.2021
7	Sinopharm / BIBP	SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	Inactivated, produced in Vero cells	+	+	+	Yakunlangan	Tasdiqlangan 07.05.2021
8	Sinovac	SARS-CoV-2 Vaccine (Vero Cell), Inactivated	Inactivated, produced in Vero cells	+	+	+	Yakunlangan	Tasdiqlangan 01.06.2021
9	Novavax	NVX-CoV2373/Covovax/Nuvaxovid	Recombinant nanoparticle prefusion spike protein formulated with Matrix-adjuvant.	+	+	+	Yakunlangan	Tasdiqlangan 17.12.2021

Manba:

Status of COVID-19 Vaccines within WHO EUL // https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_20Oct2021.pdf

Vaksinani tasdiqlagan va undan foydalanilayotgan mamlakatlar soni

2021 y. 24-dekabr holatiga ko'ra



Manbalar:

*Approved or Authorized Vaccines // <https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html>

COVID-19 Vaccine Market Dashboard //

<https://www.unicef.org/supply/covid-19-vaccine-market-dashboard>


**Tracking Coronavirus Vaccinations Around the World //

<https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html>

Mamlakatlar va kontinentlar kesimida COVID-19 ga qarshi emlanganlar soni

2021 y. 24-dekabr holatiga ko'ra

№	Davlatlar	Emlanganlar soni		Aholining umumiy sonida emlanganlarning ulushi	
		100 ta kishiga	Jami	Bitta doza bilan emlangan	To'liq emlangan
	Dunyo	115	8 851 618 912	59%	49%
1	BAA	227	22 181 292	99%	92%
2	Bruney	182	790 506	93%	89%
3	Kuba	259	29 404 770	91%	84%
4	Chili	228	43 175 145	91%	87%
5	Portugaliya	184	18 946 447	89%	88%
6	Xitoy	195	2 719 459 000	88%	85%
7	Malta	203	1 019 517	87%	87%
8	Kambodja	182	30 029 819	86%	83%
9	Janubiy Koreya	190	98 220 575	85%	82%
10	Kanada	176	66 253 753	84%	78%




Manba:
Tracking Coronavirus Vaccinations Around the World // <https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html>



COVID-19 ga qarshi vaksinalarning narxi

2021 y. 24-dekabr holatiga ko'ra

No	Vaksinaning ishlab chiqaruvchisi	Vaksinalarning narxi (bitta doza uchun)*
1	Pfizer	\$6,75-18,90
2	AstraZeneca/University of Oxford	\$2,19-5
3	Serum institute of India	\$3-13,27
4	Sinopharm	\$144,27 (2 ta doza uchun)
5	Sinovac	\$10,30-29,75
6	Moderna	\$15-37
7	Janssen	\$8,50-10
8	The Gamaleya National Center (Sputnik V)	\$11-19,90



Manba:

* COVID-19 Vaccine Market Dashboard //

[https://www.unicef.org/supply/covid-19-vaccine-market-](https://www.unicef.org/supply/covid-19-vaccine-market-dashboard?utm_source=facebook&utm_medium=organic&utm_campaign=coronavirus&fbclid=IwAR101804JupyKfUU1u6osTc-nNVGj7kiYDI8eJtiMUgjEIALGhYO3w0EE)

[dashboard?utm_source=facebook&utm_medium=organic&utm_campaign=coronavirus&fbclid=IwAR101804JupyKfUU1u6osTc-nNVGj7kiYDI8eJtiMUgjEIALGhYO3w0EE](https://www.unicef.org/supply/covid-19-vaccine-market-dashboard?utm_source=facebook&utm_medium=organic&utm_campaign=coronavirus&fbclid=IwAR101804JupyKfUU1u6osTc-nNVGj7kiYDI8eJtiMUgjEIALGhYO3w0EE)



PSST Lotin Amerikasida ishlab chiqarilgan birinchi COVID-19 vaksinasining xalqaro tasdiqlanganini ma'qullashdi

Panamerika sog'liqni saqlash tashkiloti (PSST) Argentina va Meksika litsenziyasi bo'yicha Lotin amerikasida ishlab chiqarilayotgan, birinchi COVID-19 ga qarshi AstraZeneca preparatini Jahon sog'liqni saqlash tashkiloti ro'yhatiga kiritishni maqulladi [5].



"Lotin Amerikasida ishlab chiqarilgan birinchi COVID-19 vaksinasi xalqaro qo'llab-quvvatlanganini ta'kidlaymiz. Preparatning JSST favqulodda vaziyatlar ro'yxatiga kiritilishi pandemiya davrida vaktsinalar soni ortayotganini tasdiqlaydi", - deyiladi PSST bayonotida. Ta'kidlashicha, ushbu tashkilot direktori Karissa Eten, JSSTning qarorini

Lotin Amerikasi uchun muhim bosqich ekanligini va mintaqada sifatli koronavirus vaktsinalari mavjudligini kengaytirish uchun texnologiya transferi muhimligini ta'kidladi [6].

"Preparatning JSST tomonidan xalqaro qo'llab-quvvatlashi Lotin Amerikasi va Karib havzasi vaktsinalarni global yetkazib berishga hissa qo'shishiga imkon yaratadi, bu esa vaktsinadan foydalanishdagi mavjud bo'shliqlarni bartaraf etishda muhim rol o'ynaydi", dedi Eten [7].

AstraZeneca vaktsinasi Argentinaning mAbxiyence farmatsevtika kompaniyasi tomonidan ishlab chiqarilgan va preparatni qadoqlash bilan Meksikaning Laboratorios Liomont kompaniyasi shug'ullanadi. Ushbu kompaniyalar hamkorligida ishlab chiqaradigan vaktsina, allaqachon Lotin Amerikasi va Karib havzasidagi bir qancha mamlakatlarda qo'llanilmoqda. JSST ro'yxatiga kiritilishi preparatni mintaqadan tashqarida yetkazib berish, shuningdek, xalqaro COVAX mexanizmi bo'yicha tarqatish uchun yo'l ochadi.



Lancet: Xitoyning Ad5-nCoV COVID-19 vaksinasi xavfsiz va samarali

Xitoyda ishlab chiqilgan Ad5-nCoV vaksinasining samaradorligi simptomatik COVID-19ga qarshi 57,5% va og'ir koronavirusga qarshi 91,7% samarali. Samaradorlik vakcina yuborilgandan 28 kun o'tgach yuzaga keladi. Bu haqda ma'lumot, klinik sinovlarning 3-bosqichidan o'tgan tadqiqot natijalar ko'rsatdi [8].



Vakcina bilan jiddiy nojo'ya ta'sirlar yoki o'lim holatlari qayd etilmagan. Olimlarning ta'kidlashicha, preparat barqaror immunitet reaksiyasini keltirib chiqaradi.

Belgilangan nojo'ya ta'sirlarga inyeksiya joyida og'riq, bosh og'rig'i, uyquchanlik va yengil, o'rtacha umumiy mushak og'rig'i mkuzatiladi.



Ad5-nCoV CanSino Biologics Inc va Pekin biotexnologiya instituti tomonidan ishlab chiqilgan. Bu bir martalik virusli vektor vaksinasidir. Preparatni saqlash harorati 2 dan 8 darajagacha noldan yuqori.

Preparat tadqiqot sinovlari o'tkazilgan 10 mamlakatlarda, jumladan, Argentina, Chili, Meksika va Pokistonda tasdiqlangan. Hozirda

ushbu klinik sinovda ishtirok etgan Rossiyada tartibga soluvchi tekshiruvlar olib borilmoqda [9].

"Bizning tadqiqotimiz natijalariga ko'ra, Ad5-nCoV ning bir dozasi jiddiy kasalliklarga qarshi juda samarali, shuningdek, butun dunyo bo'ylab sog'liqni saqlash tizimlariga COVID-19 sababli yuqori darajada jiddiy kasallikdan yoki kasalxonaga yotqizish zaruratidan yuklanadigan og'irlikni yengillashtirishga yordam beradi.

Bundan tashqari, vakcina bir inyeksiyadan so'ng og'ir kasalliklarga qarshi samarali bo'lganligi sababli, u vaksinadan foydalanishni yaxshilashga yordam beradi, ayniqsa past va o'rta daromadli mamlakatlarda ikki dozali asosiy vakcina bilan qo'llanilishdan ko'ra ancha samarali" dedi tadqiqot bosh muallifi Kanadaning Dalhousiye universiteti doktori Skott Xelperin.



SARS-COV-2 koronavirusning eng zaif shtammi e'lon qilindi

Edinburg universiteti vakillari COVID-19 koronavirusining biroz kuchsiz va hatto uning eng zaif mutatsiyasini aniqlashga muvaffaq bo'ldi [10].

Ilmiy ish natijalariga ko'ra, koronavirus infeksiyasining oxirgi varianti shunday nomlandi, unga "Omicron" nomi berildi.

Xitoyning Vuxan shahrida kasallik avj olgandan beri aniqlangan barcha mutatsiyalar ichida Omicron eng zaiflardan biri hisoblangan [11].



Shuningdek, Omicron koronavirusning eng zaif varianti deb topilgan tadqiqot hali ko'rib chiqilmaganini, ya'ni uni ilmiy asoslangan deb hisoblash mumkin emasligini ham ta'kidlaymiz. Shunga qaramay, ekspertlar Omicron koronavirusi odamlar uchun katta xavf tug'dirmasligiga va o'lim sonining keskin o'sishiga olib kelmasligiga ishonch berishmoqda [12].

Bundan tashqari, yangi shtammdan kelib chiqqan COVID-19 asoratlarni rivojlanish ehtimoli virusning oldingi versiyalariga qaraganda ancha past.

Tadqiqot davomida mutaxassislar emlash davomida bemorlarning yoshi, jinsi, o'tmishdagi kasalliklari va boshqalar kabi ma'lumotlarni hisobga olgan holda amalga oshiriladi.

Natijada, Omicron koronavirusi bilan kasallangan holda kasalxonaga yotqizish Delta shtammiga nisbatan 60% kamroq ekanligi ma'lum bo'ldi. Shu bilan birga, "Omicron" "Delta" ni siqib chiqara boshlaydi. Bu jarayon infeksiyaning odamdan odamga tezroq va osonroq o'tishi bilan izohlanadi.

Yana bir bor mutatsiyaga uchragan koronavirusga qarshi emlash hali ham samarali ekanligini tasdiqlaydi, ammo omikrondan himoyalani uchun kuchaytiruvchi doza talab qilinadi.



Hindistonda 15 yoshdan oshgan o'smirlar COVID-19 ga qarshi emlanadi

Hindiston kelasi yilning yanvar oyidan boshlab 15 yoshdan oshgan o'smirlarni koronavirusga qarshi emlashni boshlaydi, dedi Bosh vazir Narendra Modi [13].

"3-yanvardan boshlab 15 yoshdan 18 yoshgacha bo'lgan o'smirlar emlanish huquqiga ega bo'ladilar. Bu mamlakatdagi bolalarni maktabda himoya qilishga, shuningdek, ularning ota-onalariga ham yordam beradi. Bizning front xodimlarimiz kasallikka qarshi kurashda oldingi saflarda bo'ladi. 10-yanvar oyidan boshlab 60 yoshdan oshgan va yon kasalliklarga chalinganlar ham kuchaytiruvchi vaksina olish huquqiga ega bo'ladi", – dedi bosh vazir.

Modi, shuningdek, yaqin orada Hindistonda koronavirusga qarshi nazal vaksina va dunyodagi birinchi DNK vaksinalari taqdim etilishini ta'kidladi [14].



1. Reported Cases and Deaths by Country, Territory, or Conveyance // <https://www.worldometers.info/coronavirus/> (26.12.2021)
2. Approved or Authorized Vaccines // <https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html> (26.12.2021)
3. COVID-19 Vaccine Market Dashboard // <https://www.unicef.org/supply/covid-19-vaccine-market-dashboard> (26.12.2021)
4. Tracking Coronavirus Vaccinations Around the World // <https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html> (26.12.2021)
5. PAHO welcomes international endorsement of first COVID-19 vaccine produced in Latin America // <https://www.paho.org/en/news/23-12-2021-paho-welcomes-international-endorsement-first-covid-19-vaccine-produced-latin> (26.12.2021)
6. ВОЗ одобрила первую производимую по лицензии в Латинской Америке вакцину // <https://regnum.ru/news/society/3461035.html> (26.12.2021)
7. ВОЗ одобрила для применения первую вакцину, производимую по лицензии в Латинской Америке // <https://tass.ru/obschestvo/13289825/amp> (26.12.2021)
8. Lancet: китайская вакцина Ad5-nCoV от COVID-19 безопасна и эффективна // <https://poisknews.ru/koronavirus/lancet-kitajskaya-vakczina-ad5-ncov-ot-covid-19-bezopasna-i-effektivna/> (26.12.2021)
9. The Lancet: Phase 3 trial reports one dose of Ad5-nCoV COVID-19 vaccine is safe and effective, including against severe disease // <https://www.eurekalert.org/news-releases/938820> (26.12.2021)
10. Назван самый слабый штамм коронавируса SARS-CoV-2 // <https://www.google.com/amp/s/www.belnovosti.by/amp/obshchestvo/nazvan-samyj-slabyy-shtamm-koronavirusa-sars-c0v-2> (26.12.2021)
11. Real-world data from U.K. suggests omicron is less likely than delta to send people to the hospital // https://www.washingtonpost.com/world/europe/omicron-severity-uk/2021/12/22/303d4d26-6337-11ec-9b51-7131fa190c5e_story.html (26.12.2021)
12. Учёные назвали самый слабый штамм Covid-19 // https://www.024.by/2021/12/uchyonye-nazvali-samyj-slabyj-shtamm-covid-19/?utm_source=yxnews&utm_medium=mobile (26.12.2021)
13. Подростков старше 15 лет начнут прививать от COVID-19 в Индии // <https://www.google.com/amp/s/www.belta.by/amp/world/view/podrostkov-starshe-15-let-nachnut-privivat-ot-covid-19-v-indii-476716-2021/> (26.12.2021)
14. В Индии начнут вакцинировать от COVID-19 подростков старше 15 лет // <https://ria.ru/amp/20211225/vaktsinatsiya-1765495974.html> (26.12.2021)

**COVID
19**

**Coronavirus
Vaccine**



O'zbekiston Respublikasi Innovatsion rivojlanish vazirligi huzuridagi
Ilmiy-texnik axborot markazi

Toshkent-2021